Diabetic nephropathy Dr,Sh.Sajjadieh Nephrologist

  • View
    213

  • Download
    1

Embed Size (px)

Transcript

  • Slide 1
  • Diabetic nephropathy Dr,Sh.Sajjadieh Nephrologist
  • Slide 2
  • Why is Diabetic Nephropathy Important?
  • Slide 3
  • Diabetic Nephropathy Over 40% of new cases of end-stage renal disease (ESRD) are attributed to diabetes. In 2001, 41,312 people with diabetes began treatment for end-stage renal disease. In 2001, it cost $22.8 billion in public and private funds to treat patients with kidney failure.
  • Slide 4
  • Slide 5
  • Diabetes: The Most Common Cause of ESRD Primary Diagnosis for Patients Who Start Dialysis Diabetes 50.1% Hypertension 27% Glomerulonephritis 13% Other 10% United States Renal Data System. Annual data report. 2000. No. of patients Projection 95% CI 1984 1988 1992 1996 2000 2004 2008 0 100 200 300 400 500 600 700 r 2 =99.8% 243,524 281,355 520,240 No. of dialysis patients (thousands)
  • Slide 6
  • Slide 7
  • DN-PATHOLOGY GBM THICKENING MESANGIAL SCLEROIS - DIFFUSE -NODULAR (Kimmelstiel- Wilson) FIBRIN CAP/CAPSULAR DROP ARTERIOLAR HYALINOSIS INTERSTITIAL FIBROSIS ISHEAMIC CHANGES PYELONEPHRITIC CHANGES.
  • Slide 8
  • Take Message 1 Diabetic nephropathy is progressive kidney disease Most common cause of ESRD Lowering blood pressure with RAAS blockade is critical Combinations of ACEi + ARB Prevent cardiovascular morbidity and mortality
  • Slide 9
  • Diabetic Nephropathy Most common cause of nephrotic syndrome in adults. Leading cause of ESRD in USA 30% of patients with Type I and 20% of patients with Type II DM develop diabetic nephropathy. Initially microalbuminuria followed by heavy proteinuria and decline in renal function. Diagnosis usually made on clinical grounds and biopsy not needed.
  • Slide 10
  • What is the Natural History of Diabetic Nephropathy?
  • Slide 11
  • Definition of Diabetic Nephropathy Clinical diagnosis based on Hx, Exam and urine albumin/creatinine ratio in most cases Longstanding History of diabetes + retinopathy Macroalbuminuria (a.k.a overt nephropathy) defined as random urine albumin/creatinine ratio > 300 mg/g Hypertension (> 90%) Renal Biopsy confirmation is rare
  • Slide 12
  • DIAGNOSIS OF DIABETIC NEPHROPAHTY MICROALBUMINURIAMICROALBUMINURIA - urine albumin>30mg/d & 30mg/d & 300mg/day. Establish retinopathy. Absence of features sugg. of Non- Diabetic renal disease.
  • Slide 13
  • Natural History of Diabetic Nephropathy Declining GFR Time GFR ESRD Hypertension BP Time Glomerular Basement Membrane Podocytes Foot process Damaged Endothelium Albumin-rich filtrate Albuminuria Albumin Leak GFR Cardiovascular Death Risk CV Risk (fold ) 20 15 10 5 1 0 20 40 60 80 100
  • Slide 14
  • Development of Macroalbuminuria Heralds Rapid Decline in Glomerular Filtration in Type II Diabetes
  • Slide 15
  • Diabetics with Macroalbuminuria are More Likely to Die than Develop ESRD CVDEATHCVDEATH Elevated Serum Creatinine 19% No albuminruia 1.4% 2.0% Microalbuminruia 3.0% 2.8% Macroalbuminruia 4.6% 2.3% The United Kingdom Prospective Diabetes Study (approx. 5000 Type 2 Diabetics) Newly diagnosed, predominantly white, medically treated
  • Slide 16
  • What are Diabetics with Nephropathy Dying From? Stroke Myocardial Infarction Heart Failure Sudden Death
  • Slide 17
  • Improving Outcomes in Diabetic Nephropathy Prevention of Cardiovascular Events Prevention of End-Stage Renal Disease Diabetic Nephropathy
  • Slide 18
  • Diabetic Nephropathy: Take Message 2 Leading cause of end-stage kidney disease Characterized by hypertension, proteinuria and progressive loss of kidney function Cardiovascular complications excessive an increase with worsening kidney function More likely to die than progress to end- stage
  • Slide 19
  • Slide 20
  • Definition of Abnormal Albuminuria in Diabetes Mellitus MicroalbuminuriaMacroalbuminuria (Nephropathy) Detected by dipstick NoYes Urine Albumin / Cr 30 - 299 mg Alb / g Cr > 300 mg Alb / g Cr Renal RiskMarker of future nephropathy in some Marker progressive renal disease Cardiovascular Risk Increased
  • Slide 21
  • Five Stages of Kidney Disease Stage 1: Hyperfiltration, or an increase in glomerular filtration rate (GFR) occurs. Kidneys increase in size. Stage 2: Glomeruli begin to show damage and microalbuminurea occurs. Stage 3: Albumin excretion rate (AER) exceeds 200 micrograms/minute, and blood levels of creatinine and urea- nitrogen rise. Blood pressure may rise during this stage.
  • Slide 22
  • Five Stages of Kidney Disease (cont.) Stage 4: GFR decreases to less than 75 ml/min, large amounts of protein pass into the urine, and high blood pressure almost always occurs. Levels of creatinine and urea-nitrogen in the blood rise further. Stage 5: Kidney failure, or end stage renal disease (ESRD). GFR is less than 10 ml/min. The average length of time to progress from Stage 1 to Stage 4 kidney disease is 17 years for a person with type 1 diabetes. The average length of time to progress to Stage 5, kidney failure, is 23 years.
  • Slide 23
  • STAGES OF DN STAGE-1 HYPERFILTRATION STAGE-2 SILENT STAGE STAGE-3 INCIPIENT NEPHROPATHY STAGE-4 OVERT NEPHROPATHY STAGE-5 CHRONIC RENAL FAILURE
  • Slide 24
  • DIABETIC NEPHROPATHY Stage 1& 2( GFR): lasts about 5 to15 years Stage 3 ( microalbuminuria or 30 300 mg albumin/day): lasts 1 -5 years and strongly predicts diabetic nephropathy and increases cardiovascular mortality. Stage 4 (overt proteinuria): detected by dip stick and risk for worsening of HTN & decline in renal function Stage 5(renal failure): ESRD 7-10 yrs after onset of overt proteinuria
  • Slide 25
  • DIABETIC NEPHROPATHY TYPE 2 ONSET NOT KNOWN. MAY PRESENT IN ANY STAGE. HTN MAY PRECEDE DN. 60% OF DN HAVE RETINOPATHY. NON-DIABETIC RENAL DISEASE HIGH. TYPE 1 ONSET WELL KNOWN. PROGRESS STAGE BY STAGE. HTN ALWAYS AFTER STAGE-3. >90% OF DN HAVE RETINOPATHY. NON-DIABETIC RENAL DISEASE LOW.
  • Slide 26
  • Slide 27
  • PREVENTION OF DIABETIC NEPHROPATHY Identification of high risk patients. Role of treatment of HTN Role of glycemic control. Role of acei therapy. Treatment of hyperlipidemia Ident. Of non-diabetic renal disease & specific treatment
  • Slide 28
  • Screening for Diabetic Nephropathy 1 American Diabetes Association: Nephropathy in Diabetes (Position Statement). Diabetes Care 27 (Suppl.1): S79-S83, 2004
  • Slide 29
  • What is the Proper Therapy of Kidney Disease in patients with Diabetes?
  • Slide 30
  • The Renal Injury Triad Angiotensin II ProteinuriaHypertension
  • Slide 31
  • Treatment of Diabetic Nephropathy Hypertension Control - Goal: lower blood pressure to
  • Slide 32
  • Glycemic Control Preprandial plasma glucose 90-130 mg/dl A1C
  • How I do get My Patients BP to the Goal of 50 ml/min, thiazide eGFR < 50 ml/min, loop diuretic Long-Acting CCB or -blocker Long-acting -blocker vs clonidine Minoxidil
  • Slide 34
  • Slide 35
  • Multiple Risk Factor Intervention Improves Outcomes in Type 2 diabetics with Microalbuminuria Randomized, open-label, target driven, long-term intensified intervention trial aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria BP < 130/80, (all treated with an ACEi or ARB) A1c < 6.5% Total Cholesterol < 175 mg/dl Total Triglyceride 150 mg/dl Aspirin 80 mg daily Exercise program Smoking Cessation
  • Slide 36
  • Slide 37
  • Slide 38
  • Is Combination Therapy With An ACE Inhibitor And An ARB Safe And Effective For Patients With Diabetic Renal Disease?
  • Slide 39
  • ACEi- or ARB-Based Regimens for Diabetic Nephropathy Do Not Go Far Enough! ACEi or ARB GFR = - 6 ml/min/yr Time to ESRD 6.6 yrs Time (yrs) ESRD 50 2 4 6 8 10 Glomerular Filtration Rate ml/min/1.73 m 2 No ACEi/ARB or BP control GFR = - 10 ml/min/yr Time to ESRD 4 yrs 40 30 20 10 ACEi + ARB GFR = - ? ml/min/yr Time to ESRD ? RAAS blockade + Other?
  • Slide 40
  • Slide 41
  • Is There a Role for Spironolactone (or Eplerenone) in Combination with Other Drugs in Patients with Diabetic Nephropathy?
  • Slide 42
  • Adverse Renal and Cardiovascular Effects of Aldosterone Glomerulosclerosis Interstitial Fibrosis Proteinuria Renal Failure Ventricular Hypertrophy Cardiac Fibrosis Contractile Dysfunction Heart Failure Endothelial dysfunction Inflammation Oxidative Stress Aldosterone
  • Slide 43
  • Mineralocorticoid Receptor Blockade Improves Cardiac Outcomes: Placebo Controlled Trials 36 0 10 3 4 5 6 7 8 9 2 1 63093027242118151233 Placebo Eplerenone P=0.03 RR=0.79 (95% Cl, 0.64-0.97) Cumulative Incidence of (%) Months since Randomization Eplerenone reduces sudden cardiac death Post myocardial infarction 1.00 0.00 0.95 0.90 0.85 0.80 0.75 0.70 0.65 0.60 0.55 0.50 0.45 Probability of Survival Spironolactone Placebo 3663091815122124273033 Months Spironolactone improves survival in Chronic Heart Failure P=0.001 RR=0.70 (95% Cl, 0.60-0.82
  • Slide 44
  • Ang I Ang II Progressive Diabetic Nephropathy ACE Renal Injury and Pro